BSEAGM/EGM5d ago · 14 Aug 2026, 04:38 pm

Enclosed

Everest Organics Ltd · 524790

✦ AI SummaryMgmt Change

Everest Organics Ltd has announced the outcome of its Board Meeting held on August 14, 2026. The Board approved the appointment of two independent directors, reconstituted several committees, and approved the Board's Report for the Financial Year 2025-26. The company also announced the date for its 33rd Annual General Meeting (AGM) on September 30, 2026.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Everest Organics Ltd - 524790 - The 33Rd Annual General Meeting (AGM) Of The Company Scheduled To Be Held On Wednesday, September 30, 2026 At 12.00 Noon (IST) Through Video Conferencing / Other Audio Visual Means (VC/OAVM).

Attachments (1)

📄

3553f13d-e0e3-4022-bf80-a4a16cd0fff2.pdf

pdf

Download →
View document text
Date: August 14, 2026 Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Scrip Code: 524790 Dear Sir/Madam, Sub: Outcome of the Board Meeting held on Friday, August 14, 2026. Pursuant to Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Meeting of the Board of Directors of the Company was held today, Friday, August 14, 2026. The meeting commenced at 11:30 a.m. (IST) and, after considering the appointment of Directors and the re-constitution of Committees, was adjourned at 12:00 Noon (IST) to enable a meeting of the re-constituted Audit Committee. The Board Meeting was thereafter reconvened at 01:30 p.m. (IST) and concluded at 4:10 p.m. (IST). The Board of Directors, in its Meeting, inter-alia, discussed and approved the following items of business: 1. Approved, subject to requisite approvals, the appointment of Mr. Srikanth Reddy Kolli (DIN: 06760614) as an Additional Director (Independent Category) of the Company, for a first term of five (5) consecutive years commencing from August 14, 2026. 2. Approved, subject to requisite approvals, the appointment of Mr. Subroto Banerjee (DIN: 06933525) as an Additional Director (Independent category) of the Company, for a first term of five (5) consecutive years commencing from August 14, 2026. Disclosures of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is provided as Annexure. 3. Re-constituted the following Committees of the Company with immediate effect i.e., from August 14, 2026: Audit Committee Sl No Name DIN Category Designation 1 Mr. Srikanth Reddy Kolli 06760614 Independent Director Chairman 2 Dr. Srikakarlapudi Sirisha 06921012 Managing Director Member 3 Mr. Subroto Banerjee 06933525 Independent Director Member 4 Mr. Venkata Ramana Narra 11412292 Independent Director Member Nomination and Remuneration Committee Sl No Name DIN Category Designation 1 Mr. Subroto Banerjee 06933525 Independent Director Chairman 2 Mr. Venkata Ramana Narra 11412292 Independent Director Member 3 Mr. Srikanth Reddy Kolli 06760614 Independent Director Member Stakeholders Relationship Committee Sl No Name DIN Category Designation 1 Mr. Srikanth Reddy Kolli 06760614 Independent Director Chairman 2 Dr. Srikakarlapudi Sirisha 06921012 Managing Director Member 3 Mr. Venkata Ramana Narra 11412292 Independent Director Member Corporate Social Responsibility Committee Sl No Name DIN Category Designation 1 Dr. Srikakarlapudi Sirisha 06921012 Managing Director Chairperson 2 Mr. Venkata Ramana Narra 11412292 Independent Director Member 3 Mr. Subroto Banerjee 06933525 Independent Director Member 4. Approved the Board's Report along with its annexures for the Financial Year 2025-26, forming part of the 33rd Annual Report of the Company. 5. Approved the Notice convening the 33rd Annual General Meeting (AGM) of the Company, to be held on Wednesday, September 30, 2026 at 12.00 Noon (IST) through Video Conferencing / Other Audio Visual Means (VC/OAVM). 6. The Register of Members and Share Transfer Books of the Company will remain closed from Saturday, September 26, 2026 to Wednesday, September 30, 2026 (both days inclusive), for the purpose of the 33rd Annual General Meeting (AGM) of the Company for the Financial Year 2025- 26. Friday, September 25, 2026 has been fixed as the Record Date/Cut-off Date for determining the eligibility of Members to attend and vote at the AGM (including through remote e-voting). The remote e-voting period will commence at 9.00 a.m. (IST) on Sunday, September 27, 2026 and end at 5.00 p.m. (IST) on Tuesday, September 29, 2026, and remote e-voting shall not be allowed beyond the said period. 7. Appointed Mr. Y. Ravi Prasada Reddy, Practicing Company Secretary, Proprietor of M/s. RPR & Associates, as the Scrutinizer for conducting the remote e-voting process and the venue e- voting at the 33rd Annual General Meeting of the Company, in a fair and transparent manner. 8. Approved payment of sitting fees to Non-Executive Independent Directors of the Company solely for attending Meetings of the Board and its Committees. No sitting fees shall be payable for attendance at the Annual General Meeting or any other General Meeting, or for approvals granted through Circular Resolutions of the Board or its Committees. We request you to kindly take the above information on record. Yours faithfully, For Everest Organics Limited Sirisha Srikakarlapudi Managing Director & CEO DIN: 06921012 Encl: A/a. Annexure Disclosures of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 S. Particulars Information with regard to Information with regard to No Appointment of Mr. Srikanth Appointment of Mr. Subroto Reddy Kolli Banerjee 1. Reason for change viz. Appointment of Mr. Srikanth Appointment of Mr. Subroto appointment, Reddy Kolli as Additional Director Banerjee as Additional Director reappointment, resignation, (Independent Category) for a (Independent Category) for a removal, death or otherwise. consecutive term of 5 (Five) years consecutive term of 5 (Five) subject to approval of Members years subject to approval of of the Company. Members of the Company. 2. Date of appointment/ re August 14, 2026, for a first term of August 14, 2026, for a first term appointment/cessation & 5 (five) consecutive years i.e., up of 5 (five) consecutive years i.e., term of appointment/re- to August 13, 2031, subject to the up to August 13, 2031, subject appointment. approval of Members. to the approval of Members. 3. Brief profile (in case of Mr. K. Srikanth Reddy Kolli, aged Subroto Banerjee, a Pharma & appointment) 44 years, is an Associate Healthcare Strategy Leader (38 Member of the Institute of yrs experience) Company Secretaries of India Current: President–Strategy & since 2010. He is registered with Founding Team, Restory the Independent Directors' Healthytech (India's 1st Databank maintained by the geriatric healthtech co.); also Indian Institute of Corporate independent consultant since Affairs. 2016 (GLG, Guidepoint, PE/VC He brings over 15 years of advisory) professional experience in Past roles: President, Strides corporate secretarial practice, Shasun (grew business corporate governance, and $7M→$32M, led 5 M&A deals); statutory/regulatory compliance Director-Oncology, Dr. Reddy's under the Companies Act, 2013 (launched India's first and the SEBI (LODR) biosimilar mAb); VP, DCA Regulations, 2015, having Imaging; Head-India, Dabur worked with several BSE and Pharma; DGM, Biological E; NSE listed companies and group plus early sales leadership at entities of large corporate Criticare & Farmitalia Carlo houses. Erba He currently serves as an Expertise: Business strategy, Independent Director of ITISH P&L leadership, M&A, market Business Solutions Limited, access, where he is a member of the oncology/biologics/critical Audit Committee and the care Nomination & Remuneration Education: B.Sc. (Physics, Committee. Chemistry, Maths), Calcutta University 4. Relation with directors of the NIL NIL Company (in case of appointment) 5. Names of other listed NIL NIL entities in which the appointing Director holds directorships, indicating the category of directorship and membership of board committees, if any. 6. Affirmation that the person Yes Yes proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority